Arcturus Therapeutics Holdings Inc (ARCT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Arcturus Therapeutics Holdings Inc (ARCT) has a cash flow conversion efficiency ratio of -0.102x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-19.44 Million) by net assets ($191.36 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See operational self-sufficiency of Arcturus Therapeutics Holdings Inc to measure how many days the company can operate on defensive assets alone.
Arcturus Therapeutics Holdings Inc - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how Arcturus Therapeutics Holdings Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Arcturus Therapeutics Holdings Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Arcturus Therapeutics Holdings Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
BlackRock Investment Quality Municipal Closed Fund
NYSE:BKN
|
0.019x |
|
Aurona Industries
TWO:8074
|
0.050x |
|
Silver Mines Ltd
AU:SVL
|
-0.008x |
|
Skue Sparebank
OL:SKUE
|
0.056x |
|
Nampak
JSE:NPK
|
0.429x |
|
QDRO Acquisition Corp. Class A Ordinary Shares
NASDAQ:QADR
|
-0.001x |
|
Asflow Co. Ltd.
KQ:159010
|
-0.025x |
|
Sporting Clube de Portugal - Futebol SAD
LS:SCP
|
-0.488x |
Annual Cash Flow Conversion Efficiency for Arcturus Therapeutics Holdings Inc (2011–2025)
The table below shows the annual cash flow conversion efficiency of Arcturus Therapeutics Holdings Inc from 2011 to 2025. For the full company profile with market capitalisation and key ratios, see market value of Arcturus Therapeutics Holdings Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $213.99 Million | $-74.27 Million | -0.347x | -39.99% |
| 2024-12-31 | $240.98 Million | $-59.75 Million | -0.248x | -281.53% |
| 2023-12-31 | $278.51 Million | $-18.10 Million | -0.065x | -154.91% |
| 2022-12-31 | $270.31 Million | $31.99 Million | 0.118x | +120.00% |
| 2021-12-31 | $228.21 Million | $-135.04 Million | -0.592x | -447.49% |
| 2020-12-31 | $396.55 Million | $-42.86 Million | -0.108x | +56.75% |
| 2019-12-31 | $25.79 Million | $-6.45 Million | -0.250x | +83.58% |
| 2018-12-31 | $13.64 Million | $-20.76 Million | -1.522x | -11079.72% |
| 2017-12-31 | $33.79 Million | $-460.00K | -0.014x | +96.66% |
| 2016-12-31 | $47.23 Million | $-19.24 Million | -0.407x | -55.64% |
| 2015-12-31 | $69.33 Million | $-18.15 Million | -0.262x | +81.57% |
| 2014-12-31 | $19.94 Million | $-28.33 Million | -1.420x | -840.49% |
| 2013-12-31 | $48.69 Million | $-7.35 Million | -0.151x | -105.40% |
| 2012-12-31 | $-567.00K | $-1.58 Million | 2.795x | +216.62% |
| 2011-12-31 | $985.00K | $-2.36 Million | -2.397x | -- |
About Arcturus Therapeutics Holdings Inc
Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system. The company also develops ARCT-032 (LUNAR-CF), an mRNA therapeutic candidate for cystic fibrosis that is in Phase 2 cli… Read more